John Schneekloth Jr., NCI, to present at Drug Design & Medicinal Chemistry
John Schneekloth Jr., Principal Investigator at the National Cancer Institute, will give a presentation at GTCbio's 11th Drug Design & Medicinal Chemistry.
- Los Angeles-Long Beach, CA (1888PressRelease) July 15, 2016 - John Schneekloth Jr., Principal Investigator at National Cancer Institute, will give a presentation on, "Targeting Structurally and Functionally Diverse Nucleic Acids with Druglike Small Molecules" at GTCbio's 11th Drug Design & Medicinal Chemistry to be held on September 12-13, 2016 in Boston, MA.
Nucleic acids represent understudied targets in medicinal chemistry. Given the advances in our knowledge about the structure and function of RNA over the past 20 years, a wealth of new targets has emerged in human disease. However, technologies to identify nucleic acid-binding molecules lag far behind those to identify protein binders. Dr. John Schneekloth will discuss his group's work on identifying nucleic acid-binding molecules. His group has developed a small molecule microarray (SMM) screening platform that can be used to rapidly screen and profile the selectivity of RNA- and DNA-binding small molecules. He will briefly discuss the technology, and the application of this approach to identify ligands for several nucleic acid targets. Of note is the discovery of a highly selective G-quadruplex-binding small molecule that silences MYC expression in an animal model of multiple myeloma.
This meeting will provide a forum for scientists across multiple disciplines, from both industry and academia, to connect and share complementary perspectives. We will discuss emerging target classes, advances in antibody drug conjugates and other methods for targeted drug delivery, new approaches in flow chemistry, and much more. In addition to scientific presentations, we will have dedicated times for networking among delegates.
Session topics include:
I. Advances in Addressing Traditional and New Target Classes
II. Targeting Protein-Protein Interactions
III. Methods for Target Identification
IV. New Opportunities for Computational Drug Design
V. Big Data in Medicinal Chemistry
For more information, please visit website: https://www.gtcbio.com/conferences/medicinal-chemistry-drug-design-overview
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com
Email: infogtcbio ( @ ) gtcbio dot com
Phone: (626) 256-6405
Fax: (626) 466-4433
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam